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Case report Axillary sentinel lymph node biopsy after 
mastectomy: a case report
Diego A Vicente*1, Leonard R Henry1,2, George Hahm1, Peter W Soballe3 and DeeDee Smart4
Abstract
Background: Sentinel lymph node biopsy has been established as the preferred method for staging early breast 
cancer. A prior history of mastectomy is felt to be a contraindication.
Case presentation: A patient with recurrent breast cancer in her skin flap was discovered to have positive axillary 
sentinel nodes by sentinel lymph node biopsy five years after mastectomy for ductal carcinoma in situ.
Conclusion: A prior history of mastectomy may not be an absolute contraindication to sentinel lymph node biopsy.
Background
Sentinel lymph node (SLN) biopsy affords staging accu-
racy equal to that of complete axillary dissection [1] with
reduced morbidity [2]. As such, it has become the pre-
ferred staging method for most patients with breast can-
cer [3]. A previous mastectomy has long been considered
a prohibitive factor for reliable SLN biopsy in cases of
recurrent cancer. We report the fifth patient, previously
treated with mastectomy, found to have metastatic breast
cancer in an axillary SLN biopsy performed at the time of
cancer recurrence.
Case presentation
A 41 year old female with DCIS of the left breast was
treated at an outside hospital in 2002 with a total mastec-
tomy. Tamoxifen was not administered. Implant based
reconstruction was accomplished. In 2007 she was
referred to our center with a 5 mm red nodule of the skin
above her left breast incision scar with a palpable density
beneath. There were no palpable axillary lymph nodes. A
biopsy of the lesion demonstrated ER positive, HER2/neu
negative invasive breast cancer.
On the morning of surgery, preoperative lymphoscin-
tigraphy was performed with injection of 250 microcuries
in the surrounding dermal component of the recurrent
tumor. Immediate and fifteen minutes lymphoscintigra-
phy with lead shield at injection site mapped to the ipsi-
lateral axillary nodal basin (Figure 1). Therefore, it was
felt that an attempt at SLN biopsy would be reasonable.
Intra-operatively, 1 mL of lymphazurin was also injected
in the dermis in four quadrants surrounding the tumor.
Three SLNs were identified, all of which were blue and
had increased radioactivity.
The recurrent tumor was widely excised and the
implant removed. Pathology revealed a 1.3 cm, ER posi-
t i v e  i n v a s i v e  b r e a s t  c a n c e r  w i t h  t h r e e  o f  t h r e e  S L N s
involved with metastatic cancer. Subsequently, the
patient received adjuvant chemotherapy with doxorubi-
cin, cyclophosphamide, and docetaxel, after which a
completion axillary lymph node dissection removed an
additional 20 nodes, which were all negative for malig-
nancy. A total of 50.4 Gy external beam radiotherapy was
administered to the left chest wall, axilla, and supraclavic-
ular areas. The patient has been receiving exemestane
and has been disease free for 33 months.
Discussion
SLN biopsy for breast cancer was rapidly assimilated into
mainstream practice shortly after its introduction by Giu-
liano et al. [4]. Consensus statements, such as the Phila-
delphia conference [5], set relatively strict guidelines to
help institute quality control and to ensure low false neg-
ative rates for this relatively new method of axillary stag-
i n g .  A s  e x p e r i e n c e  a n d  c o m f o r t  w i t h  S L N  b i o p s y  h a s
grown, studies have demonstrated feasibility and accu-
racy in staging the axilla in many clinical situations ini-
tially felt to represent contraindications [6-11].
The breast has an organized lymphatic pathway
through which breast cancer typically follows lymph from
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its primary location in the lobule into subareolar plexus
[12] and then to common lymphatic channels leading to
the axillary nodes and less commonly to the internal
mammary nodes or other surrounding sites [13,14]. A
previous breast treatment with mass excision and axillary
surgery was at first thought to significantly disrupt these
lymphatic pathways. Several studies, however, have dem-
onstrated that SLN biopsy remains feasible [15-19], but
there is a decreased identification rate of SLN and an
increased incidence of lymphatic drainage to SLN outside
of the ipsilateral axilla in this setting.
Similarly, a previous mastectomy should profoundly
interrupt the lymphatic pathway, and as such has been
held to be one of the last contraindications to SLN biopsy
in breast cancer. Our case adds to a growing literature
base that suggests that even this clinical situation may not
preclude a successful SLN biopsy [20-22]. Intra et al. first
reported on the feasibility of SLN biopsy in women with
recurrent breast cancer following mastectomy and
implant based reconstruction for previous DCIS [20]. In
this small report of four patients, SLNs were identified in
the axilla in all patients, two of whom had nodal metasta-
sis. The remaining two patients did not have nodal dis-
section. No axillary recurrences were reported, but follow
up was admittedly short. Karam et al. recently reported
on 10-year experience from the Memorial Sloan Ketter-
ing Cancer Center with attempts at SLN biopsy in the set-
ting of a previous mastectomy [21]. Of the 20 patients in
whom it was attempted, 13 (65%) had successful SLN
identification in the axilla, and nearly a 90% identification
rate was observed in those treated previously with mas-
tectomy and less than full axillary node dissection. Of the
13 patients with successful node identification, two were
found to have metastasis to the SLN. Full axillary dissec-
tion was not performed on all patients, so false negative
rates are not known; however, no patient had isolated
axillary recurrences during follow up. Most recently,
Tasevski et al. published a retrospective case series on
SLN biopsy in18 patients with ipsilateral breast tumor
recurrence after breast surgery; one of the two patients
who underwent previous mastectomy and SLN biopsy
had successful identification of a sentinel node, and it was
negative for metastasis [22].
W e cannot reliably speculate as to the origins of the
lymphatic channels by which this recurrent cancer
reached the axilla. It is possible that original lymphatic
channels maintained in the superior flap of the mastec-
tomy remained, that new collateralization of lymph chan-
nels had occurred, or perhaps that because of dermal
involvement, that this recurrent cancer utilized sub-der-
mal lymphatics similar to that of a cutaneous malignancy.
Whatever the pathway, it seems reasonable to assume
that if lymph node metastases are to occur in cases of
recurrent breast cancer, they will use the same pathway as
that taken by sulfur colloid injection near the tumor. Peri-
tumoral injection of radiocolloid therefore seems advis-
able when normal lymphatic anatomy has been pro-
foundly disrupted. If preoperative lymphoscintigraphy
maps to a nodal basin there is no reason to believe that
SLN biopsy will not be successful.
National Comprehensive Cancer Network guidelines
for breast cancer suggest that the management for cancer
recurrence after mastectomy should entail resection with
chest wall irradiation and individualized chemotherapy,
but does not describe management of axillary nodes [23].
The findings resulting from SLN biopsy in our patient
substantially affected her cancer treatment.
Conclusion
Our report, in addition to those of others, suggests that
SLN biopsy may be possible even after mastectomy. We
advocate preoperative lymphoscintigraphy in such cases,
and consideration of SLN biopsy if axillary nodal drain-
age is demonstrated. Based upon this report, we have ini-
tiated a prospective trial to identify sentinel node
identification rates in this setting. If demonstrated to be
feasible and reliable, sentinel lymph node biopsy after
mastectomy may be an important addition to the arma-
mentarium of surgical oncologists in treating patients
with recurrent breast cancer.
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